# Molecular Future

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-future

- Industry: Financial Services
- Headquarters: China
- Website: www.molecular.cc
- Total disclosed funding: $1.6M
- Latest round: Angel (Jan 17, 2018)
- Investors on record: 2

## About

Molecular Future Limited is a biotechnology company specializing in innovative solutions in molecular and biochemical sectors, providing advanced analytical tools and applications for drug discovery and diagnostics.Founded in 2017 in China, Molecular Future Limited develops advanced molecular analysis solutions. The company received CNY 25 million in March 2018 from investor China Fortune, marking its total fundraising at CNY 25 million. The founders are Jason Tso and Jayden Wei, who have a history of involvement in similar ventures.Molecular Future Limited specializes in developing innovative solutions in the molecular and biochemical sectors, focusing on advanced analytical tools and biotechnological applications. Their core offerings include high-throughput screening systems, molecular analysis software, and specialized reagents designed to enhance research and development processes in pharmaceutical and healthcare industries. These products provide precise data and insights into molecular interactions, facilitating drug discovery, diagnostics, and personalized medicine. The company serves a diverse clientele, including academic institutions, research laboratories, and pharmaceutical companies across North America, Europe, and Asia-Pacific regions.Molecular Future Limited generates revenue through a structured framework emphasizing B2B partnerships and direct transactions with research institutions and pharmaceutical companies. Their business model includes sales of proprietary software licenses and high-throughput screening systems, as well as ongoing support and maintenance services. Pricing plans for their flagship products accommodate various operational scales, allowing clients to select packages that meet their needs. These plans may encompass one-time purchases for equipment or subscriptions for software usage, promoting flexibility for customers. The company's revenue streams are reinforced by continuous engagement with clients, fostering long-term relationships that support product adoption and customer satisfaction.Molecular Future Limited plans to utilize the recent CNY 25 million funding raised in March 2018 to further develop innovative products aimed at enhancing molecular research capabilities. Additionally, the company is focusing on expanding its market presence in Europe and Asia-Pacific regions by 2025. These initiatives reflect a commitment to addressing growing demands in the pharmaceutical and healthcare sectors, aiming to introduce new product offerings that will support researchers and institutions.

## Funding rounds

- Angel, Jan 17, 2018, $1.6M — Eagles Fund, CollinStar Capital

## Investors

- Eagles Fund (https://capitalatlas.ai/funds/eagles-fund) — Angel
- CollinStar Capital — Angel